10 research outputs found
Clinical decision limits as criteria for setting analytical performance specifications for laboratory tests
Peer reviewe
Validation and verification of examination procedures in medical laboratories : opinion of the EFLM Working Group Accreditation and ISO/CEN standards (WG-A/ISO) on dealing with ISO 15189:2012 demands for method verification and validation
This paper reflects the opinion of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group Accreditation and ISO/CEN standards (WG-A/ISO). It aims to provide guidance for drawing up local/national documents about validation and verification of laboratory methods. We demonstrate how risk evaluation can be used to optimize laboratory policies to meet intended use requirements as well as requirements of standards. This is translated in a number of recommendations on how to introduce risk evaluation in various stages of the implementation of new methods ultimately covering the whole process cycle
APS calculator: A data-driven tool for setting outcome-based analytical performance specifications for measurement uncertainty using specific clinical requirements and population data
According to ISO 15189:2022, analytical performance specifications (APS) should relate to intended clinical use and impact on patient care. Therefore, we aimed to develop a web application for laboratory professionals to calculate APS based on a simulation of the impact of measurement uncertainty (MU) on the outcome using the chosen decision limits, agreement thresholds, and data of the population of interest. We developed the "APS Calculator"allowing users to upload and select data of concern, specify decision limits and agreement thresholds, and conduct simulations to determine APS for MU. The simulation involved categorizing original measurand concentrations, generating measured (simulated) results by introducing different degrees of MU, and recategorizing measured concentrations based on clinical decision limits and acceptable clinical misclassification rates. The agreements between original and simulated result categories were assessed, and values that met or exceeded user-specified agreement thresholds that set goals for the between-category agreement were considered acceptable. The application generates contour plots of agreement rates and corresponding MU values. We tested the application using National Health and Nutrition Examination Survey data, with decision limits from relevant guidelines. We determined APS for MU of six measurands (blood total hemoglobin, plasma fasting glucose, serum total and high-density lipoprotein cholesterol, triglycerides, and total folate) to demonstrate the potential of the application to generate APS. The developed data-driven web application offers a flexible tool for laboratory professionals to calculate APS for MU using their chosen decision limits and agreement thresholds, and the data of the population of interest
An approach for determining allowable between reagent lot variation
Clinicians trust medical laboratories to provide reliable results on
which they rely for clinical decisions. Laboratories fulfil their
responsibility for accurate and consistent results by utilizing an
arsenal of approaches, ranging from validation and verification
experiments to daily quality control procedures. All these procedures
verify, on different moments, that the results of a certain examination
procedure have analytical performance characteristics (APC) that meet
analytical performance specifications (APS) set for a particular
intended use. The APC can in part be determined by estimating the
measurement uncertainty component under conditions of within-laboratory
precision (u (Rw)), which comprises all components influencing the
measurement uncertainty of random sources. To maintain the adequacy of
their measurement procedures, laboratories need to distinguish aspects
that are manageable vs. those that are not. One of the aspects that may
influence u (Rw) is the momentary significant bias caused by shifts in
reagent and/or calibrator lots, which, when accepted or unnoticed,
become a factor of the APC. In this paper, we postulate a model for
allocating a part of allowable u (Rw) to between-reagent lot variation,
based on the need for long-term consistency of the measurement
variability for that specific measurand. The allocation manages the
ratio between short-term and long-term variation and indicates
laboratories when to reject or correct certain variations due to reagent
lots
Improving the laboratory result release process in the light of ISO 15189:2012 standard
The ISO 15189:2012 standard section 5.9.1 requires laboratories to
review results before release, considering quality control, previous
results, and clinical information, if any, and to issue documented
procedures about it. While laboratory result reporting is generally
regarded as part of the post-analytical phase, the result release
process requires a general view of the total examination process.
Reviewing test results may follow with troubleshooting and test
repetition, including reanalyzing an individual sample or resampling. A
systematic understanding of the result release may help laboratory
professionals carry out appropriate test repetition and ensure the
plausibility of laboratory results. In this paper, we addressed the
crucial steps in the result release process, including evaluation of
sample quality, critical result notification, result reporting, and
recommendations for the management of the result release, considering
quality control alerts, instrument flags, warning messages, and
interference indexes. Error detection tools and plausibility checks
mentioned in the present paper can support the daily practice of results
release
An approach for determining allowable between reagent lot variation
Clinicians trust medical laboratories to provide reliable results on which they rely for clinical decisions. Lab- oratories fulfil their responsibility for accurate and consistent results by utilizing an arsenal of approaches, ranging from validation and verification experiments to daily quality control procedures. All these procedures verify, on different moments, that the results of a certain examination procedure have analytical performance characteristics (APC) that meet analytical performance specifications (APS) set for a particular intended use. The APC can in part be determined by esti- mating the measurement uncertainty component under con- ditions of within-laboratory precision (uRw), which comprises all components influencing the measurement uncertainty of random sources. To maintain the adequacy of their mea- surement procedures, laboratories need to distinguish aspects that are manageable vs. those that are not. One of the aspects that may influence uRw is the momentary significant bias caused by shifts in reagent and/or calibrator lots, which, when accepted or unnoticed, become a factor of the APC. In this paper, we postulate a model for allocating a part of allowable uRw to between-reagent lot variation, based on the need for long-term consistency of the measurement variability for that specific measurand. The allocation manages the ratio between short-term and long-term variation and indicates laboratories when to reject or correct certain variations due to reagent lots
Improving the laboratory result release process in the light of ISO 15189:2012 standard
The ISO 15189:2012 standard section 5.9.1 requires laboratories to review results before release, considering quality control, previous results, and clinical information, if any, and to issue documented procedures about it. While laboratory result reporting is generally regarded as part of the post-analytical phase, the result release process requires a general view of the total examination process. Reviewing test results may follow with troubleshooting and test repetition, including reanalyzing an individual sample or resampling. A systematic understanding of the result release may help laboratory professionals carry out appropriate test repetition and ensure the plausibility of laboratory results. In this paper, we addressed the crucial steps in the result release process, including evaluation of sample quality, critical result notification, result reporting, and recommendations for the management of the result release, considering quality control alerts, instrument flags, warning messages, and interference indexes. Error detection tools and plausibility checks mentioned in the present paper can support the daily practice of results release
ISO 15189 is a sufficient instrument to guarantee high-quality manufacture of laboratory developed tests for in-house-use conform requirements of the European In-Vitro-Diagnostics Regulation: Joint opinion of task force on European regulatory affairs and working group accreditation and ISO/CEN standards of the European Federation of Clinical Chemistry and Laboratory Medicine
The EU In-Vitro Diagnostic Device Regulation (IVDR) aims for transparent risk-and purpose-based validation of diagnostic devices, traceability of results to uniquely identified devices, and post-market surveillance. The IVDR regulates design, manufacture and putting into use of devices, but not medical services using these devices. In the absence of suitable commercial devices, the laboratory can resort to laboratory-developed tests (LDT) for in-house use. Documentary obligations (IVDR Art 5.5), the performance and safety specifications of ANNEX I, and development and manufacture under an ISO 15189-equivalent quality system apply. LDTs serve specific clinical needs, often for low volume niche applications, or correspond to the translational phase of new tests and treatments, often extremely relevant for patient care. As some commercial tests may disappear with the IVDR roll-out, many will require urgent LDT replacement. The workload will also depend on which modifications to commercial tests turns them into an LDT, and on how national legislators and competent authorities (CA) will handle new competences and responsibilities. We discuss appropriate interpretation of ISO 15189 to cover IVDR requirements. Selected cases illustrate LDT implementation covering medical needs with commensurate management of risk emanating from intended use and/or design of devices. Unintended collateral damage of the IVDR comprises loss of non-profitable niche applications, increases of costs and wasted resources, and migration of innovative research to more cost-efficient environments. Taking into account local specifics, the legislative framework should reduce the burden on and associated opportunity costs for the health care system, by making diligent use of existing frameworks